Latest Feature

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Podcast: Haemonetics CEO Brian Concannon at's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Subscribe to the MassDevice
Enter your email:

Need Medtech news in a minute? We Deliver!

MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter. +3 | The top 3 medtech stories for August 20, 2014

August 20, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.


FDA delays UDI rule for contacts, intraocular lenses

August 20, 2014 by Arezu Sarvestani

The FDA gives Class III contact and intraocular lens manufacturers a 1-year extension to comply with the Unique Device Identifier program.

FDA delays UDI rule for high-risk contacts, intraocular lenses

Makers of contact lenses and intraocular lenses are getting a 1-year reprieve after the FDA agreed to shift their due date for complying with Unique Device Identifier rules.

Manufacturers successfully lobbied for a delay after demonstrating that requirements for lenses would create a massive burden for both device makers and regulators.

Covidien's atherectomy study finally hits JACC

August 20, 2014 by Arezu Sarvestani

Final results from Covidien's DEFINITIVE LE study, originally closed in 2012, finally appear in the Journal of American College of Cardiology, Cardiovascular Interventions.

Covidien's atherectomy study hits JAMA

It may have taken 2 years but final results from Covidien's (NYSE:COV) DEFINITIVE LE study finally appeared in the Journal of the American College of Cardiology's Cardiovascular Interventions issue.

Shareholders sue InVivo Therapeutics, ex-CEO Reynolds over delayed FDA trial

August 20, 2014 by Brad Perriello

Shareholders sue InVivo Therapeutics and former CEO Frank Reynolds, alleging that the company concealed how long it would take to run a clinical trial under FDA guidelines.

Shareholders sue InVivo Therapeutics over delayed FDA trial

Report: Allergan solicits Salix in bid to stymie hostile Valeant takeover

August 20, 2014 by Brad Perriello

Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.

Report: Allergan solicits Salix in bid to thwart hostile Valeant takeover

Baxter adds 200 jobs in Alabama expansion

August 20, 2014 by Arezu Sarvestani

Baxter will more than double its Opelika, Ala., workforce after putting $300 million into expanding its dialyzer manufacturing facility.

Baxter adds 200 jobs in Alabama expansion

Medtech titan Baxter (NYSE:BAX) is looking to hire 200 new workers to man its growing facility in Alabama as global demand grows for hemodialysis devices.

Ocular Therapeutix IPO reaches $75M with over-allotment

August 20, 2014 by Arezu Sarvestani

Ocular Therapeutix raises $74.8 million after under-writers grab another 750,000 shares in the company's initial public offering.

Ocular Therapeutix IPO reaches $75M

Bedford, Mass.-based Ocular Therapeutix (NSDQ:OCUL) raised $74.8 million though its initial public offering after underwriters fully exercised an over-allotment option to snag additional shares.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp